The Experts below are selected from a list of 8787 Experts worldwide ranked by ideXlab platform
Thomas C Kwee - One of the best experts on this subject based on the ideXlab platform.
-
Whole Body MRI including diffusion weighted imaging for staging lymphoma comparison with ct in a prospective multicenter study
Journal of Magnetic Resonance Imaging, 2014Co-Authors: Thomas C Kwee, Malou A Vermoolen, Erik A Akkerman, Marie Jose Kersten, Rob Fijnheer, Inge Ludwig, F J A Beek, Maarten S Van Leeuwen, Marc B Bierings, Marrie C A BruinAbstract:Purpose To compare Whole-Body magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI), to computed tomography (CT) for staging newly diagnosed lymphoma. Materials and Methods In all, 108 patients with newly diagnosed lymphoma prospectively underwent Whole-Body MRI (T1-weighted and T2-weighted short inversion time inversion recovery [n = 108], and DWI [n = 104]) and CT. Ann Arbor stages were assigned according to Whole-Body MRI and CT findings. Staging disagreements were resolved using bone marrow biopsy, FDG-PET, and follow-up studies. The results were descriptively analyzed. Results Staging results of Whole-Body MRI without DWI were equal to those of CT in 66.6%, higher in 24.1%, and lower in 9.3%, with correct/incorrect/unresolved higher staging and incorrect/unresolved lower staging relative to CT in 15/7/4 and 9/1 patient(s), respectively. Staging results of Whole-Body MRI with DWI were equal to those of CT in 65.4%, higher in 27.9%, and lower in 6.7%, with correct/incorrect/unresolved higher staging and incorrect/unresolved lower staging relative to CT in 18/6/5 and 6/1 patient(s), respectively. Conclusion The results of this study suggest that Whole-Body MRI staging equals CT staging in the majority of patients with newly diagnosed lymphoma. No advantage of additional DWI was demonstrated. Whole-Body MRI can be a good alternative to CT if radiation exposure should be avoided. J. Magn. Reson. Imaging 2014;40:26–36. © 2013 Wiley Periodicals, Inc.
-
Whole Body MRI for initial staging of paediatric lymphoma prospective comparison to an fdg pet ct based reference standard
European Radiology, 2014Co-Authors: Annemieke S Littooij, Thomas C Kwee, Ignasi Barber, Claudio Granata, Malou A Vermoolen, Goya Enriquez, Jozsef Zsiros, Shui Yen Soh, Bart De KeizerAbstract:To compare Whole-Body MRI, including diffusion-weighted imaging (Whole-Body MRI-DWI), with FDG-PET/CT for staging newly diagnosed paediatric lymphoma. A total of 36 children with newly diagnosed lymphoma prospectively underwent both Whole-Body MRI-DWI and FDG-PET/CT. Whole-Body MRI-DWI was successfully performed in 33 patients (mean age 13.9 years). Whole-Body MRI-DWI was independently evaluated by two blinded observers. After consensus reading, an unblinded expert panel evaluated the discrepant findings between Whole-Body MRI-DWI and FDG-PET/CT and used bone marrow biopsy, other imaging data and clinical information to derive an FDG-PET/CT-based reference standard. Interobserver agreement of Whole-Body MRI-DWI was good [all nodal sites together (κ = 0.79); all extranodal sites together (κ = 0.69)]. There was very good agreement between the consensus Whole-Body MRI-DWI- and FDG-PET/CT-based reference standard for nodal (κ = 0.91) and extranodal (κ = 0.94) staging. The sensitivity and specificity of consensus Whole-Body MRI-DWI were 93 % and 98 % for nodal staging and 89 % and 100 % for extranodal staging, respectively. Following removal of MRI reader errors, the disease stage according to Whole-Body MRI-DWI agreed with the reference standard in 28 of 33 patients. Our results indicate that Whole-Body MRI-DWI is feasible for staging paediatric lymphoma and could potentially serve as a good radiation-free alternative to FDG-PET/CT. • Accurate staging is important for treatment planning and assessing prognosis • Whole-Body MRI-DWI could be a good radiation-free alternative to FDG-PET/CT • Interobserver agreement of Whole-Body MRI-DWI is good • Agreement between Whole-Body MRI and the FDG-PET/CT reference standard is good • Most discrepancies were caused by suboptimal accuracy of size measurements on MRI
-
Whole Body MRI for the detection of bone marrow involvement in lymphoma prospective study in 116 patients and comparison with fdg pet
European Radiology, 2013Co-Authors: Hugo J A Adams, Thomas C Kwee, Malou A Vermoolen, Bart De Keizer, Marie Jose Kersten, Rob Fijnheer, John M H De Klerk, Judit A Adam, Jaap Stoker, Rutger Aj NievelsteinAbstract:To assess and compare the value of Whole-Body MRI with FDG-PET for detecting bone marrow involvement in lymphoma. A total of 116 patients with newly diagnosed lymphoma prospectively underwent Whole-Body MRI and blind bone marrow biopsy (BMB) of the posterior iliac crest. Of 116 patients, 80 also underwent FDG-PET. Patient-based sensitivities of Whole-Body MRI for detecting bone marrow involvement were calculated using BMB as reference standard and compared with FDG-PET in aggressive and indolent lymphomas separately. Sensitivity of Whole-Body MRI in all lymphomas was 45.5 % [95 % confidence interval (CI): 29.8–62.0 %]. Sensitivity of Whole-Body MRI in aggressive lymphoma [88.9 % (95 % CI: 54.3–100 %)] was significantly higher (P = 0.0029) than that in indolent lymphoma [23.5 % (95 % CI: 9.1–47.8 %)]. Sensitivity of FDG-PET in aggressive lymphoma [83.3 % (95 % CI: 41.8–98.9 %)] was also significantly higher (P = 0.026) than that in indolent lymphoma [12.5 % (95 % CI: 0–49.2 %)]. There were no significant differences in sensitivity between Whole-Body MRI and FDG-PET (P = 1.00) Sensitivity of Whole-Body MRI for detecting lymphomatous bone marrow involvement is too low to (partially) replace BMB. Sensitivity of Whole-Body MRI is significantly higher in aggressive lymphoma than in indolent lymphoma and is equal to FDG-PET in both entities. • Bone marrow involvement in lymphoma has prognostic and therapeutic implications. • Blind bone marrow biopsy (BMB) is standard for bone marrow assessment. • Neither Whole-Body MRI nor FDG-PET can yet replace BMB. • Both techniques have higher sensitivity in aggressive than in indolent lymphoma. • Both imaging techniques are complementary to BMB.
-
newly diagnosed lymphoma initial results with Whole Body t1 weighted stir and diffusion weighted MRI compared with 18f fdg pet ct
American Journal of Roentgenology, 2011Co-Authors: Henriette Quarles M E Van Ufford, Rutger Aj Nievelstein, Thomas C Kwee, Rob Fijnheer, F J A Beek, Maarten S Van Leeuwen, Taro Takahara, John M H De KlerkAbstract:OBJECTIVE. The purpose of this study was to compare Whole-Body MRI including diffusion-weighted imaging (DWI) with 18F-FDG PET/CT in the staging of newly diagnosed lymphoma.SUBJECTS AND METHODS. Twenty-two consecutively registered patients with newly diagnosed lymphoma prospectively underwent Whole-Body MRI (22 with T1-weighted, STIR, and DWI sequences and 21 with T1-weighted and STIR sequences but not DWI) and FDG PET/CT. Whole-Body MRI-DWI was independently evaluated by two blinded observers. Interobserver agreement was assessed, and Whole-Body MRI-DWI was compared with FDG PET/CT.RESULTS. The kappa values for interobserver agreement on Whole-Body MRI-DWI for all nodal regions together and for all extranodal regions together were 0.676 and 0.452. The kappa values for agreement between Whole-Body MRI-DWI and FDG PET/CT for all nodal regions together and for all extranodal regions together were 0.597 and 0.507. Ann Arbor stage according to Whole-Body MRI-DWI findings was concordant with that of FDG PET/CT...
Shreyas S Vasanawala - One of the best experts on this subject based on the ideXlab platform.
-
prospective comparison of 99mtc mdp scintigraphy combined 18f naf and 18f fdg pet ct and Whole Body MRI in patients with breast and prostate cancer
The Journal of Nuclear Medicine, 2015Co-Authors: Ryogo Minamimoto, Andreas M Loening, Mehran Jamali, Amir Barkhodari, Camila Mosci, Tatianie Jackson, Piotr Obara, Valentina Taviani, Sanjiv S Gambhir, Shreyas S VasanawalaAbstract:UNLABELLED We prospectively evaluated the use of combined (18)F-NaF/(18)F-FDG PET/CT in patients with breast and prostate cancer and compared the results with those for (99m)Tc-MDP bone scintigraphy and Whole-Body MRI. METHODS Thirty patients (15 women with breast cancer and 15 men with prostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI were performed after bone scintigraphy. The Whole-Body MRI protocol consisted of both unenhanced and contrast-enhanced sequences. Lesions detected with each test were tabulated, and the results were compared. RESULTS For extraskeletal lesions, (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI had no statistically significant differences in sensitivity (92.9% vs. 92.9%, P = 1.00), positive predictive value (81.3% vs. 86.7%, P = 0.68), or accuracy (76.5% vs. 82.4%, P = 0.56). However, (18)F-NaF/(18)F-FDG PET/CT showed significantly higher sensitivity and accuracy than Whole-Body MRI (96.2% vs. 81.4%, P < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs. 65.9%, P < 0.001) for the detection of skeletal lesions. Overall, (18)F-NaF/(18)F-FDG PET/CT showed higher sensitivity and accuracy than Whole-Body MRI (95.7% vs. 83.3%, P < 0.002, 87.6% vs. 76.0%, P < 0.02) but not statistically significantly so when compared with a combination of Whole-Body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs. 83.0%, P = 0.53). (18)F-NaF/(18)F-FDG PET/CT showed no significant difference from a combination of (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI. No statistically significant differences in positive predictive value were noted among the 3 examinations. CONCLUSION (18)F-NaF/(18)F-FDG PET/CT is superior to Whole-Body MRI and (99m)Tc-MDP scintigraphy for evaluation of skeletal disease extent. Further, (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI detected extraskeletal disease that may change the management of these patients. (18)F-NaF/(18)F-FDG PET/CT provides diagnostic ability similar to that of a combination of Whole-Body MRI and bone scintigraphy in patients with breast and prostate cancer. Larger cohorts are needed to confirm these preliminary findings, ideally using the newly introduced simultaneous PET/MRI scanners.
-
prospective comparison of 99mtc mdp scintigraphy combined 18f naf and 18f fdg pet ct and Whole Body MRI in patients with breast and prostate cancer
The Journal of Nuclear Medicine, 2015Co-Authors: Ryogo Minamimoto, Andreas M Loening, Mehran Jamali, Amir Barkhodari, Camila Mosci, Tatianie Jackson, Piotr Obara, Valentina Taviani, Sanjiv S Gambhir, Shreyas S VasanawalaAbstract:We prospectively evaluated the use of combined 18F-NaF/18F-FDG PET/CT in patients with breast and prostate cancer and compared the results with those for 99mTc-MDP bone scintigraphy and Whole-Body MRI. Methods: Thirty patients (15 women with breast cancer and 15 men with prostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. 18F-NaF/18F-FDG PET/CT and Whole-Body MRI were performed after bone scintigraphy. The Whole-Body MRI protocol consisted of both unenhanced and contrast-enhanced sequences. Lesions detected with each test were tabulated, and the results were compared. Results: For extraskeletal lesions, 18F-NaF/18F-FDG PET/CT and Whole-Body MRI had no statistically significant differences in sensitivity (92.9% vs. 92.9%, P = 1.00), positive predictive value (81.3% vs. 86.7%, P = 0.68), or accuracy (76.5% vs. 82.4%, P = 0.56). However, 18F-NaF/18F-FDG PET/CT showed significantly higher sensitivity and accuracy than Whole-Body MRI (96.2% vs. 81.4%, P
Sanjiv S Gambhir - One of the best experts on this subject based on the ideXlab platform.
-
prospective comparison of 99mtc mdp scintigraphy combined 18f naf and 18f fdg pet ct and Whole Body MRI in patients with breast and prostate cancer
The Journal of Nuclear Medicine, 2015Co-Authors: Ryogo Minamimoto, Andreas M Loening, Mehran Jamali, Amir Barkhodari, Camila Mosci, Tatianie Jackson, Piotr Obara, Valentina Taviani, Sanjiv S Gambhir, Shreyas S VasanawalaAbstract:UNLABELLED We prospectively evaluated the use of combined (18)F-NaF/(18)F-FDG PET/CT in patients with breast and prostate cancer and compared the results with those for (99m)Tc-MDP bone scintigraphy and Whole-Body MRI. METHODS Thirty patients (15 women with breast cancer and 15 men with prostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI were performed after bone scintigraphy. The Whole-Body MRI protocol consisted of both unenhanced and contrast-enhanced sequences. Lesions detected with each test were tabulated, and the results were compared. RESULTS For extraskeletal lesions, (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI had no statistically significant differences in sensitivity (92.9% vs. 92.9%, P = 1.00), positive predictive value (81.3% vs. 86.7%, P = 0.68), or accuracy (76.5% vs. 82.4%, P = 0.56). However, (18)F-NaF/(18)F-FDG PET/CT showed significantly higher sensitivity and accuracy than Whole-Body MRI (96.2% vs. 81.4%, P < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs. 65.9%, P < 0.001) for the detection of skeletal lesions. Overall, (18)F-NaF/(18)F-FDG PET/CT showed higher sensitivity and accuracy than Whole-Body MRI (95.7% vs. 83.3%, P < 0.002, 87.6% vs. 76.0%, P < 0.02) but not statistically significantly so when compared with a combination of Whole-Body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs. 83.0%, P = 0.53). (18)F-NaF/(18)F-FDG PET/CT showed no significant difference from a combination of (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI. No statistically significant differences in positive predictive value were noted among the 3 examinations. CONCLUSION (18)F-NaF/(18)F-FDG PET/CT is superior to Whole-Body MRI and (99m)Tc-MDP scintigraphy for evaluation of skeletal disease extent. Further, (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI detected extraskeletal disease that may change the management of these patients. (18)F-NaF/(18)F-FDG PET/CT provides diagnostic ability similar to that of a combination of Whole-Body MRI and bone scintigraphy in patients with breast and prostate cancer. Larger cohorts are needed to confirm these preliminary findings, ideally using the newly introduced simultaneous PET/MRI scanners.
-
prospective comparison of 99mtc mdp scintigraphy combined 18f naf and 18f fdg pet ct and Whole Body MRI in patients with breast and prostate cancer
The Journal of Nuclear Medicine, 2015Co-Authors: Ryogo Minamimoto, Andreas M Loening, Mehran Jamali, Amir Barkhodari, Camila Mosci, Tatianie Jackson, Piotr Obara, Valentina Taviani, Sanjiv S Gambhir, Shreyas S VasanawalaAbstract:We prospectively evaluated the use of combined 18F-NaF/18F-FDG PET/CT in patients with breast and prostate cancer and compared the results with those for 99mTc-MDP bone scintigraphy and Whole-Body MRI. Methods: Thirty patients (15 women with breast cancer and 15 men with prostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. 18F-NaF/18F-FDG PET/CT and Whole-Body MRI were performed after bone scintigraphy. The Whole-Body MRI protocol consisted of both unenhanced and contrast-enhanced sequences. Lesions detected with each test were tabulated, and the results were compared. Results: For extraskeletal lesions, 18F-NaF/18F-FDG PET/CT and Whole-Body MRI had no statistically significant differences in sensitivity (92.9% vs. 92.9%, P = 1.00), positive predictive value (81.3% vs. 86.7%, P = 0.68), or accuracy (76.5% vs. 82.4%, P = 0.56). However, 18F-NaF/18F-FDG PET/CT showed significantly higher sensitivity and accuracy than Whole-Body MRI (96.2% vs. 81.4%, P
-
pilot prospective evaluation of 99mtc mdp scintigraphy 18f naf pet ct 18f fdg pet ct and Whole Body MRI for detection of skeletal metastases
Clinical Nuclear Medicine, 2013Co-Authors: Andrei Iagaru, Phillip M Young, Erik Mittra, David W Dick, Robert J Herfkens, Sanjiv S GambhirAbstract:ObjectiveThe aim of this study was to compare 99mTc-MDP bone scanning, 18F NaF PET/CT, 18F FDG PET/CT, and Whole-Body MRI (WBMRI) for detection of known osseous metastases.Patients and MethodsThis prospective pilot trial (September 2007-April 2009) enrolled 10 participants (5 men, 5 women, 47–81 yea
Bart De Keizer - One of the best experts on this subject based on the ideXlab platform.
-
Whole Body MRI for initial staging of paediatric lymphoma prospective comparison to an fdg pet ct based reference standard
European Radiology, 2014Co-Authors: Annemieke S Littooij, Thomas C Kwee, Ignasi Barber, Claudio Granata, Malou A Vermoolen, Goya Enriquez, Jozsef Zsiros, Shui Yen Soh, Bart De KeizerAbstract:To compare Whole-Body MRI, including diffusion-weighted imaging (Whole-Body MRI-DWI), with FDG-PET/CT for staging newly diagnosed paediatric lymphoma. A total of 36 children with newly diagnosed lymphoma prospectively underwent both Whole-Body MRI-DWI and FDG-PET/CT. Whole-Body MRI-DWI was successfully performed in 33 patients (mean age 13.9 years). Whole-Body MRI-DWI was independently evaluated by two blinded observers. After consensus reading, an unblinded expert panel evaluated the discrepant findings between Whole-Body MRI-DWI and FDG-PET/CT and used bone marrow biopsy, other imaging data and clinical information to derive an FDG-PET/CT-based reference standard. Interobserver agreement of Whole-Body MRI-DWI was good [all nodal sites together (κ = 0.79); all extranodal sites together (κ = 0.69)]. There was very good agreement between the consensus Whole-Body MRI-DWI- and FDG-PET/CT-based reference standard for nodal (κ = 0.91) and extranodal (κ = 0.94) staging. The sensitivity and specificity of consensus Whole-Body MRI-DWI were 93 % and 98 % for nodal staging and 89 % and 100 % for extranodal staging, respectively. Following removal of MRI reader errors, the disease stage according to Whole-Body MRI-DWI agreed with the reference standard in 28 of 33 patients. Our results indicate that Whole-Body MRI-DWI is feasible for staging paediatric lymphoma and could potentially serve as a good radiation-free alternative to FDG-PET/CT. • Accurate staging is important for treatment planning and assessing prognosis • Whole-Body MRI-DWI could be a good radiation-free alternative to FDG-PET/CT • Interobserver agreement of Whole-Body MRI-DWI is good • Agreement between Whole-Body MRI and the FDG-PET/CT reference standard is good • Most discrepancies were caused by suboptimal accuracy of size measurements on MRI
-
Whole Body MRI for the detection of bone marrow involvement in lymphoma prospective study in 116 patients and comparison with fdg pet
European Radiology, 2013Co-Authors: Hugo J A Adams, Thomas C Kwee, Malou A Vermoolen, Bart De Keizer, Marie Jose Kersten, Rob Fijnheer, John M H De Klerk, Judit A Adam, Jaap Stoker, Rutger Aj NievelsteinAbstract:To assess and compare the value of Whole-Body MRI with FDG-PET for detecting bone marrow involvement in lymphoma. A total of 116 patients with newly diagnosed lymphoma prospectively underwent Whole-Body MRI and blind bone marrow biopsy (BMB) of the posterior iliac crest. Of 116 patients, 80 also underwent FDG-PET. Patient-based sensitivities of Whole-Body MRI for detecting bone marrow involvement were calculated using BMB as reference standard and compared with FDG-PET in aggressive and indolent lymphomas separately. Sensitivity of Whole-Body MRI in all lymphomas was 45.5 % [95 % confidence interval (CI): 29.8–62.0 %]. Sensitivity of Whole-Body MRI in aggressive lymphoma [88.9 % (95 % CI: 54.3–100 %)] was significantly higher (P = 0.0029) than that in indolent lymphoma [23.5 % (95 % CI: 9.1–47.8 %)]. Sensitivity of FDG-PET in aggressive lymphoma [83.3 % (95 % CI: 41.8–98.9 %)] was also significantly higher (P = 0.026) than that in indolent lymphoma [12.5 % (95 % CI: 0–49.2 %)]. There were no significant differences in sensitivity between Whole-Body MRI and FDG-PET (P = 1.00) Sensitivity of Whole-Body MRI for detecting lymphomatous bone marrow involvement is too low to (partially) replace BMB. Sensitivity of Whole-Body MRI is significantly higher in aggressive lymphoma than in indolent lymphoma and is equal to FDG-PET in both entities. • Bone marrow involvement in lymphoma has prognostic and therapeutic implications. • Blind bone marrow biopsy (BMB) is standard for bone marrow assessment. • Neither Whole-Body MRI nor FDG-PET can yet replace BMB. • Both techniques have higher sensitivity in aggressive than in indolent lymphoma. • Both imaging techniques are complementary to BMB.
Ryogo Minamimoto - One of the best experts on this subject based on the ideXlab platform.
-
prospective comparison of 99mtc mdp scintigraphy combined 18f naf and 18f fdg pet ct and Whole Body MRI in patients with breast and prostate cancer
The Journal of Nuclear Medicine, 2015Co-Authors: Ryogo Minamimoto, Andreas M Loening, Mehran Jamali, Amir Barkhodari, Camila Mosci, Tatianie Jackson, Piotr Obara, Valentina Taviani, Sanjiv S Gambhir, Shreyas S VasanawalaAbstract:UNLABELLED We prospectively evaluated the use of combined (18)F-NaF/(18)F-FDG PET/CT in patients with breast and prostate cancer and compared the results with those for (99m)Tc-MDP bone scintigraphy and Whole-Body MRI. METHODS Thirty patients (15 women with breast cancer and 15 men with prostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI were performed after bone scintigraphy. The Whole-Body MRI protocol consisted of both unenhanced and contrast-enhanced sequences. Lesions detected with each test were tabulated, and the results were compared. RESULTS For extraskeletal lesions, (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI had no statistically significant differences in sensitivity (92.9% vs. 92.9%, P = 1.00), positive predictive value (81.3% vs. 86.7%, P = 0.68), or accuracy (76.5% vs. 82.4%, P = 0.56). However, (18)F-NaF/(18)F-FDG PET/CT showed significantly higher sensitivity and accuracy than Whole-Body MRI (96.2% vs. 81.4%, P < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs. 65.9%, P < 0.001) for the detection of skeletal lesions. Overall, (18)F-NaF/(18)F-FDG PET/CT showed higher sensitivity and accuracy than Whole-Body MRI (95.7% vs. 83.3%, P < 0.002, 87.6% vs. 76.0%, P < 0.02) but not statistically significantly so when compared with a combination of Whole-Body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs. 83.0%, P = 0.53). (18)F-NaF/(18)F-FDG PET/CT showed no significant difference from a combination of (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI. No statistically significant differences in positive predictive value were noted among the 3 examinations. CONCLUSION (18)F-NaF/(18)F-FDG PET/CT is superior to Whole-Body MRI and (99m)Tc-MDP scintigraphy for evaluation of skeletal disease extent. Further, (18)F-NaF/(18)F-FDG PET/CT and Whole-Body MRI detected extraskeletal disease that may change the management of these patients. (18)F-NaF/(18)F-FDG PET/CT provides diagnostic ability similar to that of a combination of Whole-Body MRI and bone scintigraphy in patients with breast and prostate cancer. Larger cohorts are needed to confirm these preliminary findings, ideally using the newly introduced simultaneous PET/MRI scanners.
-
prospective comparison of 99mtc mdp scintigraphy combined 18f naf and 18f fdg pet ct and Whole Body MRI in patients with breast and prostate cancer
The Journal of Nuclear Medicine, 2015Co-Authors: Ryogo Minamimoto, Andreas M Loening, Mehran Jamali, Amir Barkhodari, Camila Mosci, Tatianie Jackson, Piotr Obara, Valentina Taviani, Sanjiv S Gambhir, Shreyas S VasanawalaAbstract:We prospectively evaluated the use of combined 18F-NaF/18F-FDG PET/CT in patients with breast and prostate cancer and compared the results with those for 99mTc-MDP bone scintigraphy and Whole-Body MRI. Methods: Thirty patients (15 women with breast cancer and 15 men with prostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. 18F-NaF/18F-FDG PET/CT and Whole-Body MRI were performed after bone scintigraphy. The Whole-Body MRI protocol consisted of both unenhanced and contrast-enhanced sequences. Lesions detected with each test were tabulated, and the results were compared. Results: For extraskeletal lesions, 18F-NaF/18F-FDG PET/CT and Whole-Body MRI had no statistically significant differences in sensitivity (92.9% vs. 92.9%, P = 1.00), positive predictive value (81.3% vs. 86.7%, P = 0.68), or accuracy (76.5% vs. 82.4%, P = 0.56). However, 18F-NaF/18F-FDG PET/CT showed significantly higher sensitivity and accuracy than Whole-Body MRI (96.2% vs. 81.4%, P
